Rocket Pharmaceuticals (RCKT) Stock Statistics & Valuation Metrics

Rocket Pharmaceuticals has a market cap or net worth of $327.58M. The enterprise value is $298.37M.

Rocket Pharmaceuticals has 109,193,550 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rocket Pharmaceuticals’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is -75.38%.

The current PE Ratio of Rocket Pharmaceuticals is ―. Rocket Pharmaceuticals’s PEG ratio is 0.07.

In the last 12 months, Rocket Pharmaceuticals had revenue of 0.00 and earned -223.12M in profits. Earnings per share was -2.01.

In the last 12 months, operating cash flow was -179.63M and capital expenditures -169.00K, giving a free cash flow of -179.79M billion.

Rocket Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Rocket Pharmaceuticals upcoming earnings date is Aug 10, 2026, Before Open (Confirmed).

Rocket Pharmaceuticals as a current ratio of 6.38, with Debt / Equity ratio of 10.40%

In the past 12 months, Rocket Pharmaceuticals has paid 0.00 in taxes.

Rocket Pharmaceuticals EV to EBITDA ratio is -1.60, with an EV/FCF ratio of -1.77.

Rocket Pharmaceuticals has $144.38M in cash and marketable securities with $24.76M in debt, giving a net cash position of $119.61M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Rocket Pharmaceuticals is $9.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy